
DRUG DEVELOPMENT TRACK
Offers both CME & CPE Credit
UAN #JA4008220-0000-20-019-H05-P
ACPE – 2 CONTACT HOURS/KNOWLEDGE-BASED

CO-CHAIRS:
Olanrewaju Okusanya, PharmD, MS, Team Leader, US Food & Drug Administration
Vadryn Pierre, PharmD, Director, Clinical Pharmacology, EMD Serono Inc

TARGET AUDIENCE:
This Symposium will be useful for drug discovery and development scientists, clinical pharmacologists, preclinical pharmacologists and toxicologists, clinician scientists, systems pharmacology scientists, mathematical biologists and regulatory scientists.

GOALS & OBJECTIVES:
Following the completion of this activity, the learner will be able to:
1. Explain the challenges in evaluating novel therapies in patients that require therapies known to be either drug-drug interaction victims or perpetrators;
2. Review the challenges in selecting initial doses for First-in-Human evaluation in patients that are on therapies known to be perpetrators of drug-drug interactions;
3. Discuss approaches that allow for the initiation of doses in the presence of interacting concomitant medications;
4. Evaluate the use of quantitative clinical pharmacology and in vivo/in vitro data to support initial dose selection without compromising safety.